An early stage biotech company based in the Netherlands, pioneering novel therapies using its proprietary SureTAC™ precision membrane protein degradation platform. The company focuses on selective degradation of membrane-bound targets involved in autoimmune and inflammatory diseases.
Leadership & Board
Current Number of Employees23
Current LinkedIn Followers2,084
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$12M
Total Amount Raised$12M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$12M
Latest Funding Amount$12M
Latest Funding RoundSeed Round
Latest Funding RoundSeed Round
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
Laigo Bio had 23 employees as of September 7, 2026. The number of employees increased by 0 (0.00%) week-over-week.
23Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
Laigo Bio had 2,084 followers as of September 7, 2026. The number of followers increased by 4 (0.19%) week-over-week.
2,084Latest Followers Count
4(0.19%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.